Jae-Uk Jeong, Chai Hong Rim, Gyu Sang Yoo, Won Kyung Cho, Eui Kyu Chie, Yong Chan Ahn, Jong Hoon Lee, on behalf of Korean Oligometastasis Working Group, Korean Cancer Association
Cancer Res Treat. 2024;56(3):809-824. Published online December 14, 2023
Purpose
There is increasing interest in the efficacy of stereotactic ablative radiotherapy (SABR) for treating colorectal cancer (CRC) patients with oligometastases (OM), recently. The purpose of this meta-analysis was to evaluate local control (LC), progression-free survival (PFS), and overall survival (OS) of CRC patients with pulmonary OM treated with SABR and toxicities.
Materials and Methods
Studies that reported SABR for CRC patients with pulmonary OM were searched from MEDLINE and Embase. Treatment outcomes including LC, PFS, OS, and toxicities of grade 3 or higher were assessed.
Results
A total of 19 studies with 1,668 patients were chosen for this meta-analysis. Pooled 1-, 2-, and 3-year LC rates were 83.1%, 69.3%, and 63.9%, respectively. PFS rates were 44.8%, 26.5%, and 21.5% at 1, 2, and 3 years, respectively. OS rates at 1-, 2-, and 3-year were 87.5%, 69.9%, and 60.5%, respectively. The toxicity rate of grade 3 or higher was 3.6%. The effect of dose escalation was meta-analyzed using available studies.
Conclusion
Application of SABR to CRC patients with pulmonary OM achieved modest local control with acceptable toxicity according to the present meta-analysis. Further studies establishing the clinical efficacy of SABR are guaranteed.
Citations
Citations to this article as recorded by
Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim Cancer Research and Treatment.2025; 57(1): 11. CrossRef
Won Kyung Cho, Gyu Sang Yoo, Chai Hong Rim, Jae-Uk Jeong, Eui Kyu Chie, Yong Chan Ahn, Hyeon-Min Cho, Jun Won Um, Yang-Gun Suh, Ah Ram Chang, Jong Hoon Lee, On behalf of the Oligometastasis Working Group, Korean Cancer Association
Cancer Res Treat. 2023;55(4):1281-1290. Published online June 7, 2023
Purpose Despite numerous studies on the optimal treatments for oligometastatic disease (OMD), there is no established interdisciplinary consensus on its diagnosis or classification. This survey-based study aimed to analyze the differential opinions of colorectal surgeons and radiation oncologists regarding the definition and treatment of OMD from the colorectal primary.
Materials and Methods A total of 141 participants were included in this study, consisting of 63 radiation oncologists (44.7%) and 78 colorectal surgeons (55.3%). The survey consisted of 19 questions related to OMD, and the responses were analyzed using the chi-square test to determine statistical differences between the specialties.
Results The radiation oncologists chose “bone” more frequently compared to the colorectal surgeons (19.2% vs. 36.5%, p=0.022), while colorectal surgeons favored “peritoneal seeding” (26.9% vs. 9.5%, p=0.009). Regarding the number of metastatic tumors, 48.3% of colorectal surgeons responded that “irrelevant, if all metastatic lesions are amendable to local therapy”, while only 21.8% of radiation oncologist chose same answer. When asked about molecular diagnosis, most surgeons (74.8%) said it was important, but only 35.8% of radiation oncologists agreed.
Conclusion This study demonstrates that although radiation oncologists and colorectal surgeons agreed on a majority of aspects such as diagnostic imaging, biomarker, systemic therapy, and optimal timing of OMD, they also had quite different perspectives on several aspects of OMD. Understanding these differences is crucial to achieving multidisciplinary consensus on the definition and optimal management of OMD.
Citations
Citations to this article as recorded by
Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives Eui Kyu Chie, Chai Hong Rim, Won Kyung Cho, Yong Chan Ahn Cancer Research and Treatment.2023; 55(4): 1063. CrossRef
Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee, on behalf of Korean Cancer Association Oligometastasis Working Group
Cancer Res Treat. 2023;55(3):707-719. Published online March 15, 2023
Introduction of the concept for oligometastasis led to wide application of metastasis-directed local ablative therapies for metastatic colorectal cancer (CRC). By application of the metastasis-directed local ablative therapies including surgical resection, radiofrequency ablation (RFA), and stereotactic ablative body radiotherapy (SABR), the survival outcomes of patients with metastatic CRC have improved. The liver is the most common distant metastatic site in CRC patients, and recently various metastasis-directed local therapies for hepatic oligometastasis from CRC (HOCRC) are widely used. Surgical resection is the first line of metastatic-directed local therapy for HOCRC, but its eligibility is very limited. Alternatively, RFA can be applied to patients who are ineligible for surgical resection of liver metastasis. However, there are some limitations such as inferior local control (LC) compared with surgical resection and technical feasibility based on location, size, and visibility on ultrasonography of the liver metastasis. Recent advances in radiation therapy technology have led to an increase in the use of SABR for liver tumors. SABR is considered complementary to RFA for patients with HOCRC who are ineligible for RFA. Furthermore, SABR can potentially result in better LC for liver metastases > 2-3 cm compared with RFA. In this article, the previous studies regarding curative metastasis-directed local therapies for HOCRC based on the radiation oncologist’s and surgeon’s perspective are reviewed and discussed. In addition, future perspectives regarding SABR in the treatment of HOCRC are suggested.
Citations
Citations to this article as recorded by
Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim Cancer Research and Treatment.2025; 57(1): 11. CrossRef
Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer Hwa Kyung Byun, Gyu Sang Yoo, Soo-Yoon Sung, Jin-Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Yeon Joo Kim, Yeon-Sil Kim, Kyung Su Kim Radiation Oncology Journal.2024; 42(4): 247. CrossRef
Purpose
This study aimed to compare the early hematological dynamics and acute toxicities between proton beam craniospinal irradiation (PrCSI) and photon beam craniospinal irradiation (PhCSI) for pediatric brain tumors.
Materials and Methods
We retrospectively reviewed patients with pediatric brain tumors who received craniospinal irradiation (CSI). The average change in hemoglobin levels (ΔHbavg), absolute lymphocyte counts (ΔALCavg), and platelet counts (ΔPLTavg) from baseline values was evaluated and compared between the PrCSI and PhCSI groups at 1 and 2 weeks after the initiation of CSI, 1 week before and at the end of radiotherapy, and 3-4 weeks after the completion of radiotherapy using t test and mixed-model analysis.
Results
The PrCSI and PhCSI groups consisted of 36 and 30 patients, respectively. There were no significant differences in ΔHbavg between the two groups at any timepoint. However, ΔALCavg and ΔPLTavg were significantly lower in the PhCSI group than in PrCSI group at every timepoint, demonstrating that PrCSI resulted in a significantly lower rate of decline and better recovery of absolute lymphocyte and platelet counts. The rate of grade 3 acute anemia was significantly lower in the PrCSI group than in in the PhCSI group.
Conclusion
PrCSI showed a lower rate of decline and better recovery of absolute lymphocyte and platelet counts than PhCSI in the CSI for pediatric brain tumors. Grade 3 acute anemia was significantly less frequent in the PrCSI group than in the PhCSI group. Further large-scale studies are warranted to confirm these results.
Citations
Citations to this article as recorded by
Pediatric CNS Radiation Oncology: Recent Developments and Novel Techniques Justin Oh, Samir Patel, Mary-Pat Schlosser, Andrew J. Arifin, Carol Oliveira, Anne-Marie Charpentier, Derek S. Tsang Current Oncology.2025; 32(3): 180. CrossRef
Acute side effects of proton and photon radiotherapy for medulloblastoma: a retrospective national multicenter study Linn Söderlund Diaz, Måns Agrup, Anna Askild, Anna Embring, Jacob Engellau, Ingrid Fagerström Kristensen, Anna Flejmer, Charlotta Fröjd, Martin P Nilsson, Anna Maja Svärd, Angelica Walfridsson, Malin Blomstrand Journal of Neuro-Oncology.2025;[Epub] CrossRef
Long-term effects of local radiotherapy on growth and vertebral features in children with high-risk neuroblastoma Kyungmi Yang, Joong Hyun Ahn, Sook-Young Woo, Sang Hoon Jung, Ki Woong Sung, Ji Won Lee, Do Hoon Lim BMC Pediatrics.2024;[Epub] CrossRef
Comparison of Craniospinal Irradiation Using Proton Beams According to Irradiation Method and Initial Experience Treating Pediatric Patients Nobuyoshi Fukumitsu, Hikaru Kubota, Masayuki Mima, Yusuke Demizu, Takeshi Suzuki, Daiichiro Hasegawa, Yoshiyuki Kosaka, Atsufumi Kawamura, Toshinori Soejima Advances in Radiation Oncology.2023; 8(5): 101251. CrossRef
Proton versus photon radiation therapy: A clinical review Zhe Chen, Michael M. Dominello, Michael C. Joiner, Jay W. Burmeister Frontiers in Oncology.2023;[Epub] CrossRef
Shifting Strategies in the Treatment of Pediatric Craniopharyngioma Segev Gabay, Thomas E. Merchant, Frederick A. Boop, Jonathan Roth, Shlomi Constantini Current Oncology Reports.2023; 25(12): 1497. CrossRef
Particle therapy is a promising and evolving modality of radiotherapy that can be used to treat tumors that are radioresistant to conventional photon beam radiotherapy. It has unique biological and physical advantages compared with conventional radiotherapy. The characteristic feature of particle therapy is the “Bragg peak,” a steep and localized peak of dose, that enables precise delivery of the radiation dose to the tumor while effectively sparing normal organs. Especially, the charged particles (e.g., proton, helium, carbon) cause a high rate of energy loss along the track, thereby leading to high biological effectiveness, which makes particle therapy attractive. Using this property, the particle beam induces more severe DNA double-strand breaks than the photon beam, which is less influenced by the oxygen level. This review describes the general biological and physical aspects of particle therapy for oncologists, including non-radiation oncologists and beginners in the field.
Citations
Citations to this article as recorded by
Tuning the range-energy relationship parameter for Monte Carlo-based proton Bragg curve spreading in muscle, bone, and polymethylmethacrylate Behzad Aminafshar, Hamid Reza Baghani, Ali Asghar Mowlavi Radiological Physics and Technology.2025; 18(1): 300. CrossRef
Evaluation of machine learning models for predicting xerostomia in adults with head and neck cancer during proton and heavy ion radiotherapy Lijuan Zhang, Zhihong Zhang, Yiqiao Wang, Yu Zhu, Ziying Wang, Hongwei Wan Radiotherapy and Oncology.2025; 204: 110712. CrossRef
Physiopathological effects of entrance versus distal spread-out Bragg peak on mouse spinal cord neurons Filippo Torrisi, Francesco Paolo Cammarata, Valentina Bravatà, Marco Calvaruso, Cristiana Alberghina, Anna Maria Pavone, Giada Petringa, Giuseppe Antonio Pablo Cirrone, Simona Denaro, Anna Gervasi, Simona D’Aprile, Nunzio Vicario, Emanuele Scifoni, Pietro Scientific Reports.2025;[Epub] CrossRef
Effect of FLASH proton therapy on primary bronchial epithelial cell organoids Merian E. Kuipers, Floriane van Liefferinge, Ernst van der Wal, Marta Rovituso, Annelies M. Slats, Pieter S. Hiemstra, Krista C.J. Van Doorn-Wink Clinical and Translational Radiation Oncology.2025; 52: 100927. CrossRef
Exploring biochemical considerations for diffusive alpha radiation therapy (DaRT) models Peter Dukakis, Jesús J. Bosque, Alejandro Bertolet Physica Medica.2025; 131: 104947. CrossRef
STAT1 increases the sensitivity of lung adenocarcinoma to carbon ion irradiation via HO-1-mediated ferroptosis Yanliang Chen, Dandan Wang, Hongtao Luo, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Qiuning Zhang, Wenzhen Yuan Molecular and Cellular Biochemistry.2025;[Epub] CrossRef
Uncertainty evaluation in simulation study on range-shift estimation due to statistical noise in secondary electron bremsstrahlung from a small number of carbon ions Michiko Tsuda, Mitsutaka Yamaguchi, Takuya Yabe, Yuto Nagao, Naoki Kawachi, Makoto Sakai, Tomihiro Kamiya, Wataru Kada, Hiroshi Watabe Japanese Journal of Applied Physics.2025; 64(4): 047001. CrossRef
Monte Carlo simulation of beam quality correction factor kQ
for carbon-ion beams using FLUKA and GATE for selected cylindrical and plane-parallel ionization chambers Jessica Stolzenberg, Pascal Saße, Yuri Simeonov, Björn Poppe, Kilian-Simon Baumann, Hui Khee Looe Physics in Medicine & Biology.2025; 70(8): 085017. CrossRef
Effects of Combined Neutron and Proton Beam Radiation Exposure on the Pool of Breast Cancer Stem Cells In Vitro I. A. Zamulaeva, O. N. Matchuk, K. A. Churyukina, V. O. Saburov, S. N. Koryakin, S. A. Ivanov, A. D. Kaprin, E. A. Krasavin Physics of Particles and Nuclei Letters.2025; 22(1): 77. CrossRef
Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report Ming-Wei Ma, Zi-Shen Wang, Hong-Zhen Li, Xian-Shu Gao, Chao Liu, Xue-Ying Ren, Wei-Li Zhang, Kai-Wei Yang Medical Dosimetry.2024; 49(1): 41. CrossRef
Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma Chia-Lun Chang, Kuan-Chou Lin, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu Radiotherapy and Oncology.2024; 190: 109971. CrossRef
The rationale for a carbon ion radiation therapy facility in Australia David I. Thwaites, Dale A. Prokopovich, Richard F. Garrett, Annette Haworth, Anatoly Rosenfeld, Verity Ahern Journal of Medical Radiation Sciences.2024; 71(S2): 59. CrossRef
Review of Recent Improvements in Carbon Ion Radiation Therapy in the Treatment of Glioblastoma Fereshteh Koosha, Mahdieh Ahmadikamalabadi, Mohadesseh Mohammadi Advances in Radiation Oncology.2024; 9(5): 101465. CrossRef
Evaluation of Helium Ion Radiotherapy in Combination with Gemcitabine in Pancreatic Cancer In Vitro Bahar Cepni, Thomas Tessonnier, Ivana Dokic, Stephan Brons, Bouchra Tawk, Andrea Mairani, Amir Abdollahi, Jürgen Debus, Klaus Herfarth, Jakob Liermann Cancers.2024; 16(8): 1497. CrossRef
A review and bibliometric analysis of global research on proton radiotherapy Ge Song, Zhi Zheng, Yingming Zhu, Yaoting Wang, Song Xue Medicine.2024; 103(19): e38089. CrossRef
Assessing the Impact of Charged Particle Radiation Therapy for Head and Neck Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis Mingyu Tan, Yanliang Chen, Tianqi Du, Qian Wang, Xun Wu, Qiuning Zhang, Hongtao Luo, Zhiqiang Liu, Shilong Sun, Kehu Yang, Jinhui Tian, Xiaohu Wang Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Biological Insights and Radiation–Immuno–Oncology Developments in Primary and Secondary Brain Tumors Fabiana Gregucci, Kathryn Beal, Jonathan P. S. Knisely, Paul Pagnini, Alba Fiorentino, Elisabetta Bonzano, Claire I. Vanpouille-Box, Babacar Cisse, Susan C. Pannullo, Philip E. Stieg, Silvia C. Formenti Cancers.2024; 16(11): 2047. CrossRef
Transcriptomic response of prostate cancer cells to carbon ion and photon irradiation with focus on androgen receptor and TP53 signaling Jörg Hänze, Lilly M. Mengen, Marco Mernberger, Dinesh Kumar Tiwari, Thomas Plagge, Andrea Nist, Florentine S. B. Subtil, Ulrike Theiss, Fabian Eberle, Katrin Roth, Matthias Lauth, Rainer Hofmann, Rita Engenhart-Cabillic, Thorsten Stiewe, Axel Hegele Radiation Oncology.2024;[Epub] CrossRef
Dose-averaged linear energy transfer within the gross tumor volume of non-small-cell lung cancer affects the local control in carbon-ion radiotherapy Guangsheng Li, Ningyi Ma, Weiwei Wang, Jian Chen, Jingfang Mao, Guoliang Jiang, Kailiang Wu Radiotherapy and Oncology.2024; 201: 110584. CrossRef
Clinical indications and future directions of carbon-ion
radiotherapy: a narrative review Seo Hee Choi, Woong Sub Koom, Hong In Yoon, Kyung Hwan Kim, Chan Woo Wee, Jaeho Cho, Yong Bae Kim, Ki Chang Keum, Ik Jae Lee The Ewha Medical Journal.2024;[Epub] CrossRef
Circadian rhythms and cancer: implications for timing in therapy Mohamed El-Tanani, Syed Arman Rabbani, Areeg Anwer Ali, Ibrahim Ghaleb Ali Alfaouri, Hamdi Al Nsairat, Israa Hamid Al-Ani, Alaa A. Aljabali, Manfredi Rizzo, Dimitrios Patoulias, Mohammad Ahmed Khan, Suhel Parvez, Yahia El-Tanani Discover Oncology.2024;[Epub] CrossRef
The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center Min Cheol Han, Seo Hee Choi, Chae-Seon Hong, Yong Bae Kim, Woong Sub Koom, Jin Sung Kim, Jaeho Cho, Chan Woo Wee, Changhwan Kim, Jong Won Park, Soorim Han, Heejeong Lee, Hong In Yoon, Ik Jae Lee, Ki Chang Keum Radiation Oncology Journal.2024; 42(4): 295. CrossRef
Preservation of Neurocognition after Proton Beam Radiation Therapy for Intracranial Tumors: First Results from REGI-MA-002015 Birgit Flechl, Lisa Konrath, Carola Lütgendorf-Caucig, Milana Achtaewa, Eugen B. Hug, Petra Georg International Journal of Radiation Oncology*Biology*Physics.2023; 115(5): 1102. CrossRef
Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity Farzad Taghizadeh-Hesary, Mohammad Houshyari, Mohammad Farhadi Journal of Cancer Research and Clinical Oncology.2023; 149(9): 6719. CrossRef
Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player Maria Manuela Rosado, Claudio Pioli Cancers.2023; 15(4): 1093. CrossRef
Particle radiotherapy for breast cancer Hanguang Ruan, Masahiko Okamoto, Tatsuya Ohno, Yang Li, Yuan Zhou Frontiers in Oncology.2023;[Epub] CrossRef
Dosimetric comparison of robust angles in carbon-ion radiation therapy for prostate cancer Han-Back Shin, Changhwan Kim, Min Cheol Han, Chae-Seon Hong, Seyjoon Park, Woong Sub Koom, Jin Sung Kim Frontiers in Oncology.2023;[Epub] CrossRef
Particle Reirradiation of Malignant Epithelial and Neuroectodermal Sinonasal Tumors: A Case Series from CNAO Barbara Vischioni, Rossana Ingargiola, Maria Bonora, Sara Ronchi, Anna Maria Camarda, Stefania Russo, Eleonora Rossi, Giuseppe Magro, Alfredo Mirandola, Ester Orlandi Journal of Clinical Medicine.2023; 12(7): 2624. CrossRef
Gold-Nanoparticles-Enhanced Production of Reactive Oxygen Species in Cells at Spread-Out Bragg Peak under Proton Beam Radiation Chang-Yun Lo, Shiao-Wen Tsai, Huan Niu, Fang-Hsin Chen, Hsiao-Chien Hwang, Tsi-Chian Chao, Ing-Tsung Hsiao, Jiunn-Woei Liaw ACS Omega.2023; 8(20): 17922. CrossRef
Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis Yanliang Chen, Hongtao Luo, Ruifeng Liu, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Zhiqiang Liu, Shilong Sun, Qiuning Zhang, Xiaohu Wang Radiation Oncology.2023;[Epub] CrossRef
Particle radiotherapy in the era of radioimmunotherapy Zihan Zhou, Bingjie Guan, Huang Xia, Rong Zheng, Benhua Xu Cancer Letters.2023; 567: 216268. CrossRef
A narrative review of particle therapy in cancer Mayakannan Krishnan, C. P. Ranjith Cancer Research, Statistics, and Treatment.2023; 6(2): 248. CrossRef
Proton Beam Therapy in the Reirradiation Setting of Brain and Base of Skull Tumour Recurrences S. Gaito, N.G. Burnet, M.C. Aznar, G. Marvaso, B.A. Jereczek-Fossa, A. Crellin, D. Indelicato, S. Pan, R. Colaco, R. Rieu, E. Smith, G. Whitfield Clinical Oncology.2023; 35(10): 673. CrossRef
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma Hwa Kyung Byun, Changhwan Kim, Jinsil Seong Clinical and Molecular Hepatology.2023; 29(4): 945. CrossRef
Proton Compared to X-Irradiation Induces Different Protein Profiles in Oral Cancer Cells and Their Derived Extracellular Vesicles Inga Solgård Juvkam, Olga Zlygosteva, Mateusz Sitarz, Bernd Thiede, Brita Singers Sørensen, Eirik Malinen, Nina Jeppesen Edin, Tine Merete Søland, Hilde Kanli Galtung International Journal of Molecular Sciences.2023; 24(23): 16983. CrossRef
DNA Damage Clustering after Ionizing Radiation and Consequences in the Processing of Chromatin Breaks Veronika Mladenova, Emil Mladenov, Martin Stuschke, George Iliakis Molecules.2022; 27(5): 1540. CrossRef
Editorial: Medical Application and Radiobiology Research of Particle Radiation Fei Ye, Chao Sun, Yi Xie, Bing Wang, Lu Cai Frontiers in Public Health.2022;[Epub] CrossRef
The Rise of Particle Beam Therapy: Are We Ready for The Potential Game-Changer? Eui Kyu Chie, Yong Chan Ahn Cancer Research and Treatment.2021; 53(3): 609. CrossRef
Purpose Proton beam therapy (PBT) is a state-of-the-art technology employed in radiotherapy (RT) for cancer patients. This study characterized how PBT has been used in clinical practice in Korea.
Materials and Methods Patients who received any type of RT between 2007 and 2019 were identified from the radiation oncology registry of the two PBT facilities operating in Korea (National Cancer Center and Samsung Medical Center). The chi-square test was used to identify patient- and treatment-related characteristics associated with the receipt of PBT.
Results A total of 54,035 patients had been treated with some form of RT in the two institutions, of whom 5,398 received PBT (10.0%). The number of patients who receive PBT has gradually increased since PBT first started, from 162 patients in 2007 to 1,304 patients in 2019. Among all types of cancer, PBT use in liver cancer has been steadily increasing from 20% in 2008-2009 to 32% in 2018-2019. In contrast, that in prostate cancer has been continuously decreasing from 20% in 2008-2009 to < 10% in 2018-2019. Male sex, very young or old age, stage I-II disease, residency in non-capital areas, a definitive setting, a curative treatment aim, enrollment in a clinical trial, re-irradiation and insurance coverage were significantly associated with the receipt of PBT (all p < 0.05).
Conclusion Since PBT started in Korea, the number of patients receiving PBT has increased to more than 1,000 per year and treatment indications have expanded. Liver cancer is the most common primary tumor among all PBT cases in Korea.
Citations
Citations to this article as recorded by
“Particle therapy - future for the Baltic states?” – synthesis of the expert workshop report Kristaps Paļskis, Erika Korobeinikova, Dace Bogorada-Saukuma, Anna Maria Camarda, Rebecca Taylor, Elena Benedetto, Edgars Mamis, Maija Radziņa, Andrejs Ērglis, Diana Adliene, Manjit Dosanjh, Maurizio Vretenar, Toms Torims Health and Technology.2024; 14(5): 965. CrossRef
Proton Therapy in The Treatment of Head And Neck Cancers- Review Kamila Bała, Yana Samovich, Karolina Dorobisz Current Oncology Reports.2024; 26(11): 1380. CrossRef
PTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer J. Isabelle Choi, Camille Hardy-Abeloos, Alicia Lozano, Alexandra Hanlon, Carlos Vargas, John H. Maduro, Julie Bradley, Birgitte Offersen, Bruce Haffty, Mark Pankuch, Richard Amos, Nalee Kim, Shannon M. MacDonald, Youlia Kirova, Robert W. Mutter Clinical and Translational Radiation Oncology.2024; 48: 100847. CrossRef
Recent trends in radiotherapy use for major cancers in Korea Kyungmi Yang, Jeong Eun Lee, Won Park, Yong Chan Ahn, Seung Jae Huh Japanese Journal of Clinical Oncology.2023; 53(12): 1177. CrossRef
Gyu Sang Yoo, Won Park, Hongryull Pyo, Byong Chang Jeong, Hwang Gyun Jeon, Minyong Kang, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Byung Kwan Park, Chan Kyo Kim, Sung Yoon Park, Ghee Young Kwon
Cancer Res Treat. 2022;54(1):218-225. Published online April 15, 2021
Purpose We aimed to investigate the risk factors and patterns of locoregional recurrence (LRR) after radical nephrectomy (RN) in patients with locally advanced renal cell carcinoma (RCC).
Materials and Methods We retrospectively analyzed 245 patients who underwent RN for non-metastatic pT3-4 RCC from January 2006 to January 2016. We analyzed the risk factors associated with poor locoregional control using Cox regression. Anatomical mapping was performed on reference computed tomography scans showing intact kidneys.
Results The median follow-up duration was 56 months (range, 1 to 128 months). Tumor extension to renal vessels or the inferior vena cava (IVC) and Fuhrman’s nuclear grade IV were identified as independent risk factors of LRR. The 5-year actuarial LRR rates in groups with no risk factor, one risk factor, and two risk factors were 2.3%, 19.8%, and 30.8%, respectively (p < 0.001). The locations of LRR were distributed as follows: aortocaval area (n=2), paraaortic area (n=4), retrocaval area (n=5), and tumor bed (n=11). No LRR was observed above the celiac axis (CA) or under the inferior mesenteric artery (IMA).
Conclusion Tumor extension to renal vessels or the IVC and Fuhrman’s nuclear grade IV were the independent risk factors associated with LRR after RN for pT3-4 RCC. The locations of LRR after RN for RCC were distributed in the tumor bed and regional lymphatic area from the bifurcation of the CA to that of the IMA.
Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study Joongwon Choi, Seokhwan Bang, Jungyo Suh, Chang Il Choi, Wan Song, Hyeong Dong Yuk, Chan Ho Lee, Minyong Kang, Seol Ho Choo, Jung Kwon Kim, Hyung Ho Lee, Jung Ki Jo, Eu Chang Hwang, Chang Wook Jeong, Young Hwii Ko, Jae Young Park, Cheryn Song, Seong Il Se Scientific Reports.2024;[Epub] CrossRef
Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction Dylan M Buller, Maria Antony, Benjamin T Ristau OncoTargets and Therapy.2023; Volume 16: 49. CrossRef
Gyu Sang Yoo, Hee Chul Park, Jeong Il Yu, Doo Ho Choi, Won Kyung Cho, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Woo Yong Lee, Hee Cheol Kim, Seong Hyeon Yun, Yong Beom Cho, Yoon Ah Park, Kyoung Doo Song, Seok-Hyung Kim, Sang Yun Ha
Cancer Res Treat. 2020;52(2):446-454. Published online September 25, 2019
Purpose
The purpose of this study was to investigate the role of carcinoembryonic antigen (CEA) levels in improving the performance of magnetic resonance imaging (MRI) for the prediction of pathologic response after the neoadjuvant chemoradiation (NCRT) for patients with rectal
cancer.
Materials and Methods
We retrospectively reviewed the medical records of 524 rectal cancer patients who underwent NCRT and total mesorectal excision between January 2009 and December 2014. The performances of MRI with or without CEA parameters (initial CEA and CEA dynamics) for prediction of pathologic tumor response grade (pTRG) were compared by receiver-operating characteristic analysis with DeLong’s method. Cox regression was used to identify the independent factors associated to pTRG and disease-free survival (DFS) after NCRT.
Results
The median follow-up was 64.0 months (range, 3.0 to 113.0 months). On multivariate analysis, poor tumor regression grade on MRI (mrTRG; p < 0.001), initial CEA (p < 0.001) and the mesorectal fascia involvement on MRI before NCRT (mrMFI; p=0.054) showed association with poor pTRG. The mrTRG plus CEA parameters showed significantly improved performances in the prediction of pTRG than mrTRG alone. All of mrTRG, mrMFI, and initial CEA were also identified as independent factors associated with DFS. The initial CEA further discriminated DFS in the subgroups with good mrTRG or that without mrMFI.
Conclusion
The CEA parameters significantly improved the performance of MRI in the prediction of pTRG after NCRT for patients with rectal cancer. The DFS was further discriminated by initial CEA level in the groups with favorable MRI parameters.
Citations
Citations to this article as recorded by
Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement Jeong Ha Lee, Nalee Kim, Jeong Il Yu, Gyu Sang Yoo, Hee Chul Park, Woo-Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Yong Beom Cho, Jung Wook Huh, Yoon Ah Park, Jung Kyong Shin, Joon Oh Park, Seung Tae Kim, Young Suk Park, Jeeyun Lee, Won Ki Kang Radiation Oncology Journal.2024; 42(2): 130. CrossRef
Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade S. Qin, Y. Chen, K. Liu, Y. Li, Y. Zhou, W. Zhao, P. Xin, Q. Wang, S. Lu, H. Wang, N. Lang Cancer/Radiothérapie.2024; 28(4): 341. CrossRef
Body composition parameters combined with blood biomarkers and magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer Jianguo Yang, Qican Deng, Zhenzhou Chen, Yajun Chen, Zhongxue Fu Frontiers in Oncology.2023;[Epub] CrossRef
Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer Xinyu Shi, Min Zhao, Bo Shi, Guoliang Chen, Huihui Yao, Junjie Chen, Daiwei Wan, Wen Gu, Songbing He Frontiers in Oncology.2022;[Epub] CrossRef
Clinical implication and management of rectal cancer with clinically suspicious lateral pelvic lymph node metastasis: A radiation oncologist’s perspective Gyu Sang Yoo, Hee Chul Park, Jeong Il Yu Frontiers in Oncology.2022;[Epub] CrossRef
High-Resolution T2-Weighted MRI to Evaluate Rectal Cancer: Why Variations Matter Kirsten L Gormly Korean Journal of Radiology.2021; 22(9): 1475. CrossRef
MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology Seong Ho Park, Seung Hyun Cho, Sang Hyun Choi, Jong Keon Jang, Min Ju Kim, Seung Ho Kim, Joon Seok Lim, Sung Kyoung Moon, Ji Hoon Park, Nieun Seo Korean Journal of Radiology.2020; 21(7): 812. CrossRef
Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Res Treat. 2019;51(3):1041-1051. Published online November 1, 2018
Purpose
We compared the oncologic outcomes of breast-conserving surgery plus radiation therapy (BCS+RT) and modified radical mastectomy (MRM) under anthracycline plus taxane-based (AT) regimens and investigated the role of adjuvant radiation therapy (RT) in patients with pathologic N1 (pN1) breast cancer treated by mastectomy.
Materials and Methods
We retrospectively reviewed the medical records of 2,011 patients with pN1 breast cancer who underwent BCS+RT or MRM alone at 12 institutions between January 2006 and December 2010. Two-to-one propensity score matching was performed for balances in variables between the groups.
Results
The median follow-up duration for the total cohort was 69 months (range, 1 to 114 months). After propensity score matching, 1,074 patients (676 in the BCS+RT group and 398 in the MRM-alone group) were analyzed finally. The overall survival, disease-free survival, locoregional failure-free survival, and regional failure-free survival (RFFS) curves of the BCS+RT group vs. MRM-alone group were not significantly different. The subgroup analysis revealed that in the group with both lymphovascular invasion (LVI) and histologic grade (HG) III, the BCS+RT showed significantly superior RFFS (p=0.008). Lymphedema (p=0.007) and radiation pneumonitis (p=0.031) occurred more frequently in the BCS+RT group than in the MRM-alone group, significantly.
Conclusion
There are no differences in oncologic outcomes between BCS+RT and MRM-alone groups under the AT chemotherapy regimens for pN1 breast cancer. However, BCS+RT group showed superior RFFS to MRM-alone group in the patients with LVI and HG III. Adjuvant RT might be considerable for pN1 breast cancer patients with LVI and HG III.
Citations
Citations to this article as recorded by
Investigation of the clinical benefits of regular breath-holding training utilizing surface guided radiation therapy technology for patients with left breast cancer Hongming Li, Zheng Miao, Jie Shen, Jianing Xiao, Zhiwei Yang, Wei Tian, Xiansong Sun, Zhen Zhou, Jing Shen, Jie Qiu Journal of Radiation Research and Applied Sciences.2025; 18(2): 101393. CrossRef
21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery Shang-Jin Xie, Run-Jie Wang, San-Gang Wu, Fu-Xing Zhang The Breast.2024; 74: 103679. CrossRef
Assessing Radiation Effects on Chemo-Treated BT20 and 4T1 Breast Cancer, and Neuroblastoma Cell Lines: A Study of Single and Multiple-Cell Ionization via Infrared Laser Trapping Mulugeta S. Goangul, Daniel B. Erenso, Ying Gao, Li Chen, Kwame O. Eshun, Gisela Alvarez, Horace T. Crogman Radiation.2024; 4(1): 85. CrossRef
Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis Kiran K Rajan, Katherine Fairhurst, Beth Birkbeck, Shonnelly Novintan, Rebecca Wilson, Jelena Savović, Chris Holcombe, Shelley Potter BJS Open.2024;[Epub] CrossRef
Radiotherapy dosimetry and radiotherapy related complications of immediate implant-based reconstruction after breast cancer surgery Yu Zhang, Fuxiu Ye, Yun Teng, Jin Zheng, Chunlu Li, Ruilan Ma, Haichen Zhang Frontiers in Oncology.2023;[Epub] CrossRef
Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients Gabriel De la Cruz Ku, Manish Karamchandani, Diego Chambergo-Michilot, Alexis R. Narvaez-Rojas, Michael Jonczyk, Fortunato S. Príncipe-Meneses, David Posawatz, Salvatore Nardello, Abhishek Chatterjee Annals of Surgical Oncology.2022; 29(10): 6163. CrossRef
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin BMC Cancer.2022;[Epub] CrossRef
Risk factors to identify the indication for regional nodal irradiation in T1-2N1M0 breast cancer: A joint analysis of 4,243 real-world cases from two institutions Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Hui Fang, Jian-Yang Wang, Jiang-Hu Zhang, Xu-Ran Zhao, Si-Ye Chen, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Ye-Xiong Li, Shu-Lian Wang Frontiers in Oncology.2022;[Epub] CrossRef
Chemo-treated 4T1 breast cancer cells radiation response measured by single and multiple cell ionization using infrared laser trap Endris Muhammed, Li Chen, Ying Gao, Daniel Erenso Scientific Reports.2019;[Epub] CrossRef